Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa Sells 8,879 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total value of $205,104.90. Following the completion of the transaction, the chief financial officer now owns 23,382 shares in the company, valued at $540,124.20. The trade was a 27.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Monday, March 17th, Mark Ragosa sold 11,464 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $23.10, for a total value of $264,818.40.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00.

Kiniksa Pharmaceuticals Trading Up 2.1 %

Shares of Kiniksa Pharmaceuticals stock opened at $23.08 on Thursday. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -164.85 and a beta of 0.48. The business’s 50 day simple moving average is $20.16 and its 200-day simple moving average is $22.08. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same quarter in the prior year, the company posted $0.35 EPS. The firm’s revenue was up 46.9% on a year-over-year basis. Sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on KNSA. Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $37.17.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in KNSA. Quarry LP acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth $50,000. Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Kiniksa Pharmaceuticals in the third quarter worth approximately $189,000. KLP Kapitalforvaltning AS bought a new position in Kiniksa Pharmaceuticals during the 4th quarter valued at $158,000. Finally, Bellevue Group AG acquired a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at $160,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.